1. Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.
- Author
-
Schewe DM, Lenk L, Vogiatzi F, Winterberg D, Rademacher AV, Buchmann S, Henry D, Bergmann AK, Cario G, and Cox MC
- Subjects
- Animals, Combined Modality Therapy, Disease Models, Animal, Hematopoietic Stem Cell Transplantation, Humans, Mice, Molecular Targeted Therapy, Oncogene Proteins, Fusion antagonists & inhibitors, Oncogene Proteins, Fusion genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology, Protein Kinase Inhibitors pharmacology, Pyrazoles pharmacology, Pyrimidines pharmacology, Recurrence, Retreatment, Treatment Outcome, Xenograft Model Antitumor Assays, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Protein Kinase Inhibitors therapeutic use, Proteins antagonists & inhibitors, Proteins genetics, Pyrazoles therapeutic use, Pyrimidines therapeutic use
- Published
- 2019
- Full Text
- View/download PDF